Co-Founder, Managing Director & CEO
VP Business Development & International Relations
Mr. Lipsky was the business development director of leading Medical Cannabis company in Israel. He brings a history of production and development to the company and has been working in the Cannabis field for the past ten years.
Mr Mitchell is a corporate finance executive with over 25 years of experience in the venture capital, equity capital markets, technology, and resources sectors. He has been involved in the founding, financing and management of both private and publicly listed companies and was instrumental in the successful LSE listing for MGC Pharma in February 2021.
Mr Mitchell is a founder and director of Chieftain Securities Pty Ltd, a Perth based Corporate Advisory & Venture Capital firm and founder and shareholder of Graft Polymer (UK) Ltd. Mr Mitchell is also currently Non-Executive Director of ASX Listed company TNT Mines Ltd (TIN), and Executive Chairman of an Australian unlisted public company, Australian Cannabis Ventures Limited.
Co-Founder, Non-Executive Director
Director & Head of Advisory Board
Dr. Ross Walker is an eminent practicing cardiologist with a passion for people and health with 40 years’ experience as a clinician. For the past 20 years he has been focusing on preventative cardiology & is one of Australia’s leading preventative health experts.
Considered one of the world’s best keynote speakers and life coaches, he is the author of seven best-selling books & a regular health presenter in the Australian Media. Dr Ross also appears weekly on the national Macquarie Radio network & the Super Radio network. He had his own national radio show, Healthy Living for 8 years on radio 2UE. Healthy Living recommenced nationally on the Macquarie Radio network on March 29th 2020.
Dr Walker runs the Sydney Heart Health Clinic in Lindfield on Sydney’s North Shore, a clinic that focuses on all aspects of non-invasive & preventative cardiology.
Dr Walker is a non-executive director for MGC Pharmaceuticals, a company researching, developing & marketing medical cannabis around the world. DR Walker is the head of the strategic advisory board for MGC & a prominent media spokesperson regarding medical cannabis.
Dr Walker is also the Chief Medical Officer for the VTN group. Dr Walker is the director of Wellness programs for the Macquarie Health Group. He is also the Chief Cardiologist for the Miskawaan Health Group, an integrative health service in South East Asia. He is also the President of the Gut Foundation of Australia. Dr Walker is the patron for Heart Support Australia.
Director & Chair of Board Committees
Stephen Parker is a seasoned executive with over thirty years’ experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategic consultant, a venture capitalist and a senior corporate financier with Baring’s, Warburg’s and Apax Partners. Stephen is currently Chairman of Sareum Holdings plc and a Non-Executive Director of Eternans Limited. Stephen has a D.Phil. from Oxford University and an MBA from City University Business School.
Evan Hayes is a highly experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes graduated with a Master of Science 1st Class Honours (Biotechnology) from the National University of Ireland, Galway and prior to this he finished first in his class from the National University of Ireland, Cork with a Bachelor of Science degree (Honours). Mr Hayes’ has also won the Daniel O’Carroll Award for Scientific Research.
Mr Hayes is currently the Asia Pacific Managing Director of Factors Group, Canada’s largest natural health company. Prior to this Mr Hayes was the Director of Sourcing and Product development at Australia’s largest natural health company, Blackmores, leading the Procurement, Technical, New product development, and Strategic sourcing divisions and managed a budget of $250m.
Joint Company Secretary
Mr Lim is a finance and corporate governance professional with over 15 years of experience working for ASX Listed companies. He has previously performed the role of Group CFO and Company Secretary at a number of ASX listed businesses including Equigold NL, Aurora Oil and Gas and Elixir Petroleum.
Mr Lim is a Certified Practicing Accountant and holds a Graduate Diploma of Applied Corporate Governance from, and is an Associate member of, the Governance Institute of Australia.
Chief Operational Officer and Deputy CEO
Ms. Friedman has 12 years of experience in Business Process Design and implementation as a Senior Consultant for Deloitte and a Project Manager in Tel-Aviv-Jaffa municipality. Ms. Friedman has experience in implementing business solutions in various industries for Enterprise and SMB organizations globally and leading cross-sectional teams.
Joint Company Secretary
Mrs. Kerr has over 10 years’ experience as a Company Secretary on both private and public companies, working on acquisitions, capital raisings, IPO’s on ASX, due diligence reviews and compliance of public companies.
Global Chief Sales Officer
Nicole has over 20 years’ experience in the pharmaceutical/healthcare industry, holding senior roles with major multi-national companies including Eli Lilly, Johnson & Johnson, Schering-Plough, Merck Sharp & Dohme and most recently Tilray. In her most recent roles as General Manager ANZ and Director of Emerging Markets at Tilray, Nicole was Instrumental in launching the first Medical Cannabis brand legally in both Australia and New Zealand, launching one of the first Medical Cannabis clinics in Australia, delivering some of Australia’s first government funded cannabis clinical trials and negotiating major exclusive government supply agreements.
Group Chief Financial Officer
Daniel has extensive experience in Corporate Finance and Accounting functions for both private and listed companies. He started his career as an auditor at BDO Australia and has worked for a large investment bank in the UK.
Over the past 10 years Daniel has worked in senior management roles for several ASX listed and large private companies in Australia.
Daniel is a qualified Chartered Accountant, a member of the Governance Institute of Australia along with the Finance Brokers Association of Australia
Chief Information Security Officer (C.I.S.O)
A veteran of both the Israeli Security Agency and the Israeli Defense Forces, Yairs experience in security management, data protection and physical cyber security ensures MGC is operating at the highest level of security, from the company’s facilities to it’s online operations and most significantly, patient data.
Yairs years of experience writing security protocols from A to Z which encompass physical security, technological systems, information security and loss prevention gives MGC the confidence to engage in global operations that are secure regardless of physical location
VP Medical Innovation
Certified neurologist in Israel, following the completion of a clinical fellowship in neuro-oncology at the MD Anderson Cancer Center in Houston, Texas, Dr. Grunfeld spent the last decades focusing on palliative care in an academic hospital in Israel. In that context, firsthand experience was gained with the medical use of cannabis for close to 5,000 patient under his personal care, giving a unique insight into issue of clinical effects, dosing, patient groups and developing treatment methodology.
Chief Medical Officer
Nadya Lisovoder is an accomplished Doctor of Medicine with 15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisovoder is a regulatory expert and has been clinical adviser to public biotech companies and a range of incubator and acceleration including Furtux- a J&J Innovation and Takeda program. Nadya has managed clinical trials across multiple therapy areas in complex, multi-site studies encompassing Israel, EU and the US for large Pharma companies such as Schering Plough, as well as innovative start-ups. Since 2012, Dr. Lisovoder has been leading for the Israeli government biomedical research in 7 hospitals in northern Israel in cooperation with universities, international Pharma companies, global CROs and biotech companies.
In 2016 Nadya founded Galilee Clinical Research Ltd, a multi- faceted entrepreneurial centre providing regulatory consulting to support product development and prepare companies for FDA meetings and filings, providing regulatory guidance for successful implementation and regulatory compliance of clinical trial programs.
VP Operations & Manufacturing
With a wealth of experience in multiple industries, from large scale agricultural rollouts to customer facing retail-oriented product development, Itay brings a focus on streamlining systems and creating efficient operations for MGC across the company’s activities. With a passion for finding the best ways for people to work together towards achieving common goals, Itay is working with all parts of the company, both geographically and operationally to ensure MGC’s efficiency and ability to scale up in the years ahead.
Chief Technology Officer
Mr. Polak, CTO, brings to the company 20 years of experience in the fields of producing products from “Lab to the market”. In his current position as CTO, Mr. Polak is managing MGC’s production IMP facility in Slovenia – Producing Medicinal products for clinical trials and early access schemes, MGC’s global Quality team- dealing with medicinal Products, herbal preparation and general regulatory issues, bringing new technology to MGC, New product introduction and scale up, and global R&D.
Mr. Polak has been a part of MGC’s management team Since 2019.
In his last position Mr. Polak was running Nano-Dimension LTD patented ink factory. This job gave Mr. Polak a deep understanding on the field of Nano formulation, and the knowledge on how to take an unknown experiment to the market – these activities include R&D, scale up, Production facility build up, team/budget/suppliers and final product management on a billion-dollar high tech company.
In 2009 Mr. Polak CO- Founded Green City urban recycling LTD, a biofuel company in the field of waste to energy, where he served as the CTO and board member.
The company had multiple production facilities globally and was first of its kind to use biological process in utilizing organic waste into Biodiesel process.
The company was owned by REFAEL-advanced defense systems, a defense corporation in 2009
Mr. Polak earned his B.Sc. In Chemistry and M.Sc. in Organic Chemistry from the Hebrew University Jer, Israel, working on the field of peptide Synthesis for drug discovery.
Chief Commercial Officer
After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.
He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.
From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.
An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.
From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.